Last reviewed · How we verify
NCT07335120: ALMANAC
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
trial in DLBCL in 800 participants. Currently enrolling.
30 October 2026
Quick facts
| Lead sponsor | The Clatterbridge Cancer Centre NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 30 October 2024 |
| Primary completion | 30 October 2026 |
| Estimated completion | 30 October 2028 |
| Sites | 1 location across United Kingdom |
Conditions studied
- DLBCL — all drugs for DLBCL →
Sponsor
The Clatterbridge Cancer Centre NHS Foundation Trust
Who can join
17 and older, any sex, with DLBCL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as chemo-immunotherapy. Currently, the best results in the treatment of LBCL is with a chemo-immunotherapy combination called R-CHOP or Pola-R-CHP. Full doses of treatment are not suitable for elderly or frail patients due to potential to cause side effects and heart problems. Such patients either receive a reduced dose called mini-R-CHOP or receive alternatives (e.g. R-GCVP or R-CEOP). Additionally, some patients treated with R-CHOP or Pola-R-CHP may not respond or may respond initially before relapsing. For these patients, treatment is not standardised, and practice varies between hospitals. ALMANAC aims to collect data about the management and outcomes of patients with LBCL who are unsuitable for standard treatments because they are not well enough to tolerate the side effects or because they have not responded or relapsed following initial treatment. In doing so, it will guide research into LBCL leading to a better understanding of this condition and better outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07335120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for DLBCL
Currently open trials in the same condition.
- NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
- NCT06758037 — Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy · Phase 2 · recruiting
- NCT06779435 — A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL · recruiting
- NCT06701357 — CR-CHOP+X in Previously Untreated DEL · Phase 2 · recruiting
- NCT06569485 — A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients · Phase 2 · recruiting
Other The Clatterbridge Cancer Centre NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07342335 — Breaking Barriers to Research Access · recruiting
- NCT04603105 — CCP Cancer UK Companion Study · active not recruiting
- NCT04622761 — Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Asses · Phase 2 · not yet recruiting
- NCT03721757 — CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer · Phase 2 · completed
- NCT04268888 — Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC · Phase 2, PHASE3 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07335120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Clatterbridge Cancer Centre NHS Foundation Trust
- Last refreshed: 12 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07335120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing